Introduction
Macular edema is a manifestation of diabetic retinopathy that can lead to central vision loss. Data from the population-based Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) study estimates the prevalence of diabetic macular edema (DME) in persons with 15 or more years of diabetes to be approximately 20% in those with type 1 diabetes, 25% in those with type 2 diabetes taking insulin and 14% in those with type 2 diabetes not taking insulin. 1 To date, the only treatment conclusively demonstrated to be of long term benefit for diabetic macular edema is focal laser photocoagulation. The Early Treatment Diabetic Retinopathy Study (ETDRS) showed that this treatment reduced the 3-year rate of moderate vision loss (3 or more lines of acuity loss) by 50%. However, only 17% of the treated eyes that had baseline acuity worse than 20/40 experienced moderate visual gain (3 or more lines of acuity improvement). 2 Thus, a therapeutic intervention that might more often restore visual acuity lost from DME remains a significant unmet medical need. Investigations of possible therapies have included intravitreal triamcinolone, oral protein kinase C inhibitors, 3 intravitreal aptamers, 4 antibodies directed against vascular endothelial growth factor (VEGF), 5-6 and vitrectomy. 7 Peribulbar injections of corticosteroids have long been used as a therapy for macular edema associated with uveitis. More recently, this treatment has been suggested for DME. Peribulbar injections have been performed using anterior subtenon's/ subconjunctival, posterior subtenon's, and retrobulbar approaches. Theoretically, adverse effects might be presumed to be lower than that of intravitreal steroids. A peribulbar corticosteroid injection is of particular interest for eyes with DME that have good visual acuity where the risks of an intravitreal injection of corticosteroid may not be justified. However, data on the efficacy and safety of peribulbar corticosteroid injections in eyes with diabetic macular edema and good acuity are lacking. Likewise data on combining a treatment such as peribulbar corticosteroids with focal laser are also lacking. Such combined therapy might provide a better outcome than either treatment alone.
To evaluate the merits of conducting a phase 3 randomized trial, we conducted a pilot study evaluating the effects of both anterior and posterior subtenon's delivery of peribulbar corticosteroids, with or without focal photocoagulation, in eyes with DME and good visual acuity.
Methods
This phase 2 randomized, multi-center clinical trial, funded by the National Eye Institute, was conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) at 32 clinical sites in the United States. The protocol and health insurance portability and accountability act (HIPAA) compliant informed consent forms were approved by multiple institutional review boards. Study oversight was provided by an independent data and safety monitoring committee. The study is listed on www.clincialtrials.gov (NCT00231023).
Study Population
Eligible subjects were at least 18 years old with type 1 or type 2 diabetes, no history of renal failure requiring dialysis or renal transplant, blood pressure not greater than 180/110 mm Hg, no current warfarin use, and at least one eye meeting study eligibility criteria. An eye was eligible if it had (1) best corrected electronic-ETDRS 8 visual acuity letter score ≥ 69 (20/40 or better), (2) definite retinal thickening due to DME based on clinical exam, (3) Optical Coherence Tomography (OCT) central subfield thickness ≥ 250 microns, (4) intraocular pressure (IOP) < 25 mm Hg with no history of open-angle glaucoma or evidence of pseudoexfoliation, (5) no evidence of vitreomacular traction as the cause of DME, (6) no prior history of intravitreal or peribulbar injections of triamcinolone acetonide or vitrectomy, (7) no history of Yttrium Aluminum Garnet (YAG) capsulotomy within the prior 2 months, panretinal scatter photocoagulation within the prior 4 months, or major ocular surgery within the prior 6 months. Prior focal photocoagulation for DME administered at least 3.5 months prior to enrollment was allowed, provided that the investigator believed that additional focal photocoagulation might still be of benefit. A subject could have two study eyes in the trial only if both were eligible at the time of study entry.
Synopsis of Study Design
After eligibility was confirmed and the informed consent obtained, each study eye was randomly assigned to one of five treatment groups on the Diabetic Retinopathy Clinical Research net (DRCR.net) website: Subjects with one study eye were randomly assigned with equal probability to one of the 5 treatment groups while those with bilateral involvement were randomly assigned to laser photocoagulation in one eye and the fellow eye to one of the other 4 treatment groups. Subjects were masked to whether the injection was anterior subtenon's or posterior subtenon's but not masked as to whether focal photocoagulation was being received. Visual acuity testers, OCT technicians, and OCT graders were masked to treatment assignment; investigators were not masked.
Follow-up visits were performed at 4, 8, 17 , and 34 weeks. The randomly assigned treatment was repeated at the 17-week visit if the thickness of the central subfield was ≥ 250 microns, or if in the judgment of the investigator, DME was still present that warranted retreatment. In the case of the combination groups, this retreatment did not include photocoagulation. Additional follow up for safety evaluations occurred through two years. Treatment after 34 weeks was at investigator discretion. Data in this report include all examinations completed through November 30, 2006, a time point at which all subjects had the opportunity for at least one year follow up.
The primary outcomes were change in visual acuity and in OCT-measured central subfield retinal thickening at 34 weeks. Frequency of retreatment was also evaluated. Elevation in intraocular pressure, development or progression of cataract, ptosis, and complications related to the treatment techniques were the main safety outcomes.
Treatment Protocols
The triamcinolone injection techniques were standardized and based on investigator usual practices. At investigator discretion, subconjunctival lidocaine 1% could be used for anesthesia. Using a 27-gauge 5/8 inch needle, the anterior injection of 20 mg triamcinolone was given beneath the bulbar conjunctiva under the lower lid and the posterior injection of 40 mg of triamcinolone was given in the subtenon's space of the superior temporal quadrant about 10 mm posterior to the limbus.
The focal photocoagulation treatment technique was modified from the original ETDRS protocol such that the laser burns were less intense (gray) and smaller (50 microns). A treatment-induced change in microaneurysm color was not required, but a burn was to be evident on the retina. Although the protocol allowed for multiple sittings to complete the treatment session, all initial treatment sessions were completed in a single sitting. Details are available at www.drcr.net.
Examination Procedures
At baseline and at each follow-up visit, best-corrected visual acuity was measured by a certified tester using an electronic procedure based on the Early Treatment Diabetic Retinopathy Study method (E-ETDRS). 8 A standardized refraction was performed at baseline and 34 weeks. At other visits, the need for refraction was determined by the investigator based on usual care considerations. At each visit, the subject was queried about adverse events and a clinical exam was performed by a certified investigator, including dilated slit lamp exam, fundus exam, and intraocular pressure measurement. Hemoglobin A1c (HbA1c) was measured and a clinical assessment was made of the extent of lens opacity at baseline, 17 and 34 weeks. Any untoward medical occurrence in a study subject, irrespective of whether or not the event was considered treatment-related, was considered an adverse event and recorded.
OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, California). Scans were 6 mm length and included the 6 radial line pattern (fast macular scan option with OCT3) for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. The OCT scans were sent to the DRCR.net Reading Center at the University of Wisconsin-Madison for grading. For 12% of the 129 baseline scans and 12% of the 489 followup scans, the automated thickness measurements were judged by the Reading Center to be inaccurate and center point thickness was manually determined and used to impute a value for the central subfield (since the correlation of the two measures was 0.99). 9 Retinal morphology was assessed from OCT images for cystoid abnormalities (five-level grading scale) and subretinal fluid (three-level grading scale).
Statistical Methods
A sample of 100 subjects with 20 randomized per group was planned for this pilot study. The primary analysis included only eligible eyes due to the main study objective of providing data on eyes meeting certain criteria for the purpose of planning a phase 3 trial (8 eyes were excluded: six eyes were determined to have central subfield thickness < 250 microns by the Reading Center grading after randomization and two eyes of one subject were noted to have proliferative diabetic retinopathy requiring scatter photocoagulation -a study exclusionimmediately after randomization and prior to study treatment being administered).
Two OCT outcomes, which are part of the automated measurements provided by the OCT machine, were principally examined: retinal thickness in the central subfield and retinal volume.
Treatment group comparisons for continuous OCT and visual acuity outcome measures were assessed using repeated measures least squares regression models adjusted for baseline values and accounting for the correlated data from subjects with two study eyes. Similarly, repeated measures generalized estimating equations (GEE) models were used for binary outcomes. Odds ratios and confidence intervals were determined from the GEE models. When outliers were truncated at ± 3 standard deviations from the mean, there was little effect on the results (data not shown). Analyses using the last observation carried forward (LOCF) imputation method gave similar results (data not shown).
Analysis of safety data combined the two anterior injection groups as well as the two posterior injection groups.
Results
Between December 2004 and September 2005, 129 eyes of 109 subjects at 32 clinical sites were assigned to receive either modified-ETDRS laser treatment (N = 38), 20 mg anterior subtenon's injection of triamcinolone (N = 23), 20 mg anterior subtenon's injection followed by laser photocoagulation after 4 weeks (N = 25), 40 mg posterior subtenon's injection of triamcinolone (N = 21), or 40 mg posterior subtenon's injection followed by laser (N = 22). Thirty-six percent of the subjects were female and 82% Caucasian; mean age was 60 ± 11 years. Mean visual acuity in the study eyes was 20/25 (letter score 79 ± 5) and mean OCT central subfield thickness was 328 ± 65 microns; 53% of eyes had received prior focal photocoagulation. Baseline characteristics by treatment group are provided in Table 1 (available at http://aaojournal.org). A slight imbalance in thickness at baseline between the treatment groups was adjusted for in the analyses and did not appreciably alter the results.
Follow-up
Three subjects died during the study unrelated to study participation (two in the posterior injection + laser treatment group and one in the posterior injection only group) and five were lost to follow up (one in the anterior injection group, three in the anterior injection + laser group, and one in the posterior injection + laser group). Among the remaining subjects, 96% of the 4-week visits, 99% of the 8-week visits, 99% of the 17-week visits, and 100% of the 34-week visits were completed, with a similar number of missed visits across each treatment group ( Figure 1 -available at http://aaojournal.org).
Treatment for DME
All eyes received the randomization-assigned treatment regimen at baseline, except one assigned to the anterior + laser group that did not receive laser treatment. Although the protocol specified that laser treatment be given 4 weeks after an injection, two eyes randomized to the posterior injection + laser group received laser more than 9 weeks after the injection was given at randomization. Prior to the 34-week visit, macular laser photocoagulation was received by one eye in the anterior injection only group and one eye randomized to laser developed neovascularization and received scatter photocoagulation. No treatment for DME other than the randomized treatment was administered to any other eyes.
At 17 weeks, the protocol specified retreatment with the randomization-assigned regimen if the central subfield was ≥ 250 microns or macular edema was still present in the investigator's judgment. Retreatment rates were 58% in the laser group, 64% in the anterior injection group, 71% in the posterior injection group, 38% in the anterior + laser group, and 43% in the posterior + laser group. The OCT data were consistent with the retreatment data with the percentages of eyes having the central subfield ≥ 250 microns being 70%, 73%, 67%, 54% and 52% in the five groups, respectively. Compared with the laser group, the odds ratio for retreatment in the two injection + laser groups combined was 0.5 (95% confidence interval 0.2 to 1.0, P = 0.04) and for the two injection only groups combined was 1.2 (95% confidence interval 0.5 to 2.9, P = 0.63).
Effect of Treatment on Retinal Thickening
There was a trend towards a reduction in retinal thickening over the 34 weeks in all five groups (Figure 2 ), but the degree of reduction in retinal thickening showed no consistent pattern across the five groups (P=0.46 comparing change in central subfield thickening from baseline to 34 weeks in the five groups, P=0.23 comparing the laser group with the two injection only groups combined, and P=0.79 comparing the laser group with the two injection plus laser groups combined (Table 2) . At the end of 34 weeks of follow up, central subfield thickness was < 250 microns in 9% to 59% of eyes in the five groups, with all but one group being between 40% and 59% (Table 3 -available at http://aaojournal.org). Results for OCT-measured macular volume were similar to the results for the central subfield (data not shown).
Effect of Treatment on Visual Acuity
At 34 weeks, the mean change in visual acuity letter score in the five groups ranged from 1 letter worse to 4 letters worse (P=0.94 comparing the 5 groups, P=0.69 comparing the laser group with the two injection only groups combined, and P=0.82 comparing the laser group with the two injection plus laser groups combined ( Table 2, Table 4 -available at http://aaojournal.org).
Adverse Effects
Ptosis was reported for 3 (6%) of 48 eyes that received an anterior injection, 5 (12%) of 43 eyes that received a posterior injection, and none of the 38 eyes receiving laser alone. There was one case of a needle penetrating the globe during a posterior injection, with no adverse sequelae.
Intraocular pressure increased by 10 mm Hg or more at any visit through the 34-week visit in 9 of 48 eyes (19%) in an anterior injection group, 5 of 43 eyes (12%) in a posterior injection group, and 2 of 38 eyes (5%) in the laser group. Intraocular pressure was ≥ 30 mm Hg in 5, 1, and 0 eyes respectively. At the time of the 34-week exam, intraocular pressure was ≥ 25 mm Hg in 7 eyes (5 in an anterior injection group and 2 in a posterior injection group). Three other eyes were being treated with intraocular pressure-lowering medications and had intraocular pressure < 25 mm Hg (2 in an anterior group and 1 in the laser group). No eyes underwent glaucoma surgery during the study.
No eyes underwent cataract extraction prior to the 34 week exam, at which time a one or more level worsening in the three-level slit lamp lens grading (none, less than standard photo, greater than or equal to standard photo) was observed on at least one of the three gradings (nuclear sclerosis, cortical, posterior subcapsular) in 6 of 38 (16%) eyes in the laser group, 11 of 44 (25%) eyes in an anterior injection group, and 10 of 39 (26%) eyes in a posterior injection group. Subsequently, 4 eyes have undergone cataract surgery (2 in an anterior injection group and 2 in a posterior injection group).
HbA1c increased from baseline by 0.5% or more in 5 of 13 subjects (38%) with a single study eye in the laser group, 14 of 38 subjects (37%) with an eye in an anterior injection group and 10 of 31 subjects (32%) with an eye in a posterior injection group.
Discussion
In this phase 2 pilot study of eyes with mild DME and good visual acuity, no clinically important effects on central retinal thickness or visual acuity were found with peribulbar injections of triamcinolone with or without follow-up focal photocoagulation in comparison with focal photocoagulation alone. Results with anterior and posterior subtenon's injections appeared similar. Although there was no benefit on visual acuity at 34 weeks, the results suggested that the need for retreatment with peribulbar triamcinolone was reduced when the injection was followed by focal photocoagulation. This observation was supported by the finding of a greater proportion of eyes with OCT central subfield thickness < 250 microns in the combined treatment groups compared with the single treatment groups. However, this observation should be viewed with caution since the investigators were not masked to treatment group. With a sample size of 40 eyes in a laser group and 40 eyes in a peribulbar triamcinolone group (the approximate sample size in this study with the two peribulbar triamcinolone without laser groups combined), a study evaluating the benefit of peribulbar triamcinolone compared with laser would have 80% power to detect a difference between groups in change in central subfield thickening of 39 microns, assuming that the true mean change in eyes receiving laser is 50 microns with a standard deviation of 60. In the study, the retinal thickening decrease averaged 38 microns in the injection only groups compared with 54 microns in the laser group (95% confidence interval for the difference, adjusting for baseline: −45 to +12 microns). More eyes in the laser group than in the injection groups had a reduction in retinal thickening of at least 50% (61% versus 33%). While the study did not have the statistical power to conclude that laser was better than peribulbar triamcinolone injections, any benefit of peribulbar triamcinolone for mild DME, if a true benefit existed, is unlikely to be more than a mean improvement of 13 microns.
As expected, elevation of intraocular pressure was a complication of treatment in some of the eyes. Ptosis, which was previously reported as a potential complication of peribulbar triamcinolone injections, 10 was observed in a few cases after both anterior and posterior injections. The duration of follow up is too short to fully evaluate the effect of the drug on cataract formation. Subsequent to the 34-week visit, 4 eyes have undergone cataract surgery in a triamcinolone group and none in the laser only group.
There have been few published studies evaluating peribulbar corticosteroids for DME. Most of the studies have involved eyes with worse acuity than in our study; results have been inconsistent. In a retrospective study, Bakri and Kaiser 10 reported on the results of posterior subtenon's injection of 40 mg of triamcinolone in 63 eyes with DME in 50 patients. Visual acuity improved from a mean of 20/80 prior to treatment to 20/63 at 12 months. A 3 or more line improvement occurred in 21%. There was a transient rise in intraocular pressure in 3 eyes and ptosis in 2 eyes. Entezari et al 11 conducted a randomized trial comparing a posterior subtenon's injection of 40 mg triamcinolone versus a placebo injection in 64 eyes with DME and mean baseline acuity of approximately 20/160 and found no benefit for visual acuity or central macular thickness. Tunc et al 12 conducted a randomized trial comparing focal laser versus focal laser combined with posterior subtenon's injection of 20 mg triamcinolone in 60 patients with DME. Mean visual acuity was 20/125 at baseline and at 18 weeks had improved on average by about 2.5 lines in the combined group versus 1.5 lines in the laser only group. On fundus photographs, improvement in macular edema was seen in 80% versus 40% in the two groups, respectively. In two randomized trials comparing posterior subtenon's injection of 40 mg triamcinolone and intravitreal injection of 4 mg triamcinolone, a greater effect on OCTmeasured central macular thickness and visual acuity was found with the intravitreal regimen. 13, 14 The study by Cardillo et al 13 included 12 patients with bilateral DME (one eye assigned to each group), with mean baseline acuity approximately 20/250. The peribulbar-treated eyes had no improvement in visual acuity but did have a decrease in mean central macular thickness from 514 microns to 365 microns at 3 months. The study by Bonini-Filho 14 included 36 patients, each with one study eye with mean baseline acuity of 20/160. In the peribulbar group, no change was seen in visual acuity or central macular thickness. A retrospective uncontrolled study also concluded that intravitreal triamcinolone has a greater effect on DME than peribulbar triamcinolone. 15
In summary, our phase 2 study did not find evidence of a clinically meaningful benefit of peribulbar corticosteroids as a treatment for mild DME. Therefore, based on these results, there is no justification to pursue a large phase 3 trial in eyes with DME and either normal or only slightly reduced visual acuity. The sample size was not sufficient to rule out a small benefit of treatment but it is unlikely that a benefit of meaningful clinical magnitude exists for peribulbar triamcinolone in cases of DME with good visual acuity. Race -N(%) White
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